Original Research ARTICLE
The Analgesic Effect of Different Concentrations of Epidural Ropivacaine Alone or Combined With Sufentanil in Patients After Cesarean Section
- Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China
Background: Patients experience moderate-high intensity postoperative pain after cesarean section (CS). The aim of this study was to investigate the optimal concentrations of ropivacaine and sufentanil for use in controlling pain after CS.
Methods: One hundred and seventy-four women undergoing elective CS were randomly allocated to four groups. Epidural analgesia was administered with 0.1% ropivacaine in the R1 group, 0.15% ropivacaine in the R2 group, a combination of 0.1% ropivacaine and 0.5 μg/ml of sufentanil in the R1S group, and a combination of 0.15% ropivacaine and 0.5 μg/ml of sufentanil in the R2S group (at a basal rate of 4 ml/h, bolus dose of 4 ml/20 min as needed). Pain scores (numerical rating scale [NRS]: 0–10 cm) at rest (NRS-R), during movement (NRS-M), and when massaging the uterus (NRS-U) were documented at 6 and 24 h. We also recorded patient satisfaction scores, time to first flatus, motor deficits, and adverse drug reactions.
Results: NRS (NRS-R, NRS-M, NRS-U) scores in the R2S group (2 [1–3], 4 [3–5], 6 [5–6], respectively) were lower than in the R1 group (3 [3–4], 5 [4–6], 7 [6–8], respectively) (p < 0.001, p < 0.05, p < 0.01, respectively) at 6 h; and patient satisfaction (9 [8–10]) was improved compared to the R1 group (8 [6–8]) (p < 0.01). The time to first flatus (18.7 ± 11.8 h) was reduced relative to the R1 group (25.9 ± 12.0 h) (p < 0.05). The time to first ambulation was not delayed (p > 0.05). However, the incidence of pruritus (4 [9.3%]) was increased compared to the R2 group (0 ) (p < 0.05) at 6 h, and the incidence of numbness (23 [53.5%], 23 [53.5%]) was increased compared to the R1 group (10 [23.3%], 10 [23.3%]) (all p < 0.01) at both 6 and 24 h.
Conclusions: Although we observed a higher incidence of pruritus and numbness, co-administration of 0.15% ropivacaine and 0.5 μg/ml of sufentanil administered epidurally optimized pain relief after CS, with treated subjects exhibiting lower NRS scores, shorter time to first flatus, and higher patient-satisfaction scores.
A surfeit of cesarean sections are performed annually worldwide. In 2016, the cesarean section (CS) rate was 31.9% (Martin et al., 2017) and 41.1% (Liang et al., 2018) in the United States and China, respectively. Despite the numerous measures used to manage pain, the incidence of inadequate analgesia after CS remains nearly 50% (Patel et al., 2017). Pain relief after CS is crucial, as poor pain relief can interfere with breast feeding and delay infant weight gain (Hirose et al., 1996). Inadequate analgesia can impair functions such as ambulation and dietary intake, and lead to complications such as thromboembolism (Leung, 2004) and postoperative ileus (inhibition of gastrointestinal motility after surgery that prevents oral intake) (Cho et al., 2017). Poor pain relief may even lead to chronic pain (Jin et al., 2016) and increased postpartum depression (Shen et al., 2020). Therefore, effective pain management after CS continues to be a relevant public health issue.
The search for the ideal method to manage postoperative pain is ongoing. Although the use of opioids is the gold standard (Kerai et al., 2017), the effects of opioids on lactation have limited intravenous opioid use—especially long-term use. Wu et al. found that patient-controlled epidural analgesia (PCEA) provided significantly superior analgesia compared with intravenous patient-controlled analgesia (PCIA) (Wu et al., 2005). Epidural morphine is commonly used for analgesia after CS (Carvalho and Butwick, 2017), but can produce a high incidence of pruritus, nausea, and vomiting (Youssef et al., 2014). These adverse drug reactions (ADRs) are difficult to prevent, and therefore modified regimens such as low concentrations of local anesthetics together with other opioids have been advocated to reduce opioid dosage and thereby decrease the incidence of bothersome ADRs. Epidural opioids also reduce the dosage of local anesthetics. A study by Gogarten et al. found that when combined with ropivacaine, sufentanil can reduce the concentration of ropivacaine required and the degree of motor blockade (Gogarten et al., 2004).
Ropivacaine has been used in labor for epidural analgesia and post-cesarean analgesia because of its lower potential for accumulation, greater sensorimotor-differential block, and increased cardiovascular safety profile (Bullingham et al., 2018; Wang et al., 2019). The breast milk/plasma concentration ratio of ropivacaine was lower than bupivacaine when administered epidurally after CS (Matsota et al., 2009), which is essential for neonatal safety. Although ropivacaine co-administered with sufentanil successfully reduced postoperative pain, few investigators have thus far evaluated the optimal concentration necessary. Therefore, we evaluated the analgesic effects by using two different concentrations (0.1% and 0.15%) of ropivacaine with or without 0.5 μg/ml of sufentanil to relieve post-cesarean pain.
Materials and Methods
This trial was conducted at the Department of Anesthesiology, Xuanwu Hospital of Capital Medical University in China. Ethics approval (ea1/185/10) was obtained from the ethics committee of the Xuanwu Hospital of Capital Medical University. The trial was registered with the Chinese clinical trial registry (ChiCTR 1900 021740), and written informed consent was obtained on the day before surgery.
Our primary aim was to compare the analgesic efficacy of the four groups at the first 24 h after CS by a prospective, randomized, double-blinded clinical trial. Our secondary objective was to compare patient satisfaction, gastrointestinal symptoms, postsurgical recovery, and ADRs among the four groups.
This trial included 174 women who were enrolled from March 2019 to September 2019. Women were eligible for inclusion if they were 21–45 years of age after 32 weeks of gestation (If the gestational age is less than 32 weeks, the newborn will be transferred to the children’s hospital, which may affect the mother’s mood) and at the American Society of Anesthesiology physical status classification I–II (Matsota et al., 2011), and were scheduled to undergo CS under neuraxial anesthesia. Patients with a known allergy to sufentanil and/or local anesthetics; a history of chronic pain, chronic opioid use, anxiolytic medication use, or drug and/or alcohol abuse; showing contraindications for neuraxial anesthesia; or manifested eclampsia, HELLP syndrome (hemolysis, elevated liver enzymes and low platelet count), or hemostatic disorders were excluded.
After pre-hydration with 500 ml of lactated Ringer’s solution, women underwent combined spinal-epidural anesthesia (CSEA) at the L2–L3 or L3–L4 spinal interspace in the right lateral position, receiving an injection containing between 7.5 and 10 mg of 0.5% hypobaric bupivacaine (Shanghai Harvest Pharmaceutical, Shanghai, China), depending upon their height (for a height <155 cm, 7.5 mg was administered; 155–160 cm, 8 mg; 160–165 cm, 8.5 mg; 165–170 cm, 9 mg; 170–175 cm, 9.5 mg; and >175 cm, 10 mg). After intrathecal injection, the epidural catheter was inserted up to 3 cm into the epidural space, and then patients were placed in a supine position in a left-lateral tilt. Once a bilateral sensory block to the T4 dermatome was achieved (which we tested by pinprick), the operation began. If sensory block was not achieved to the T4 level, 2% lidocaine (Shanghai Harvest Pharmaceutical, Shanghai, China) was administered into the epidural space to achieve adequate anesthesia, and the patients were excluded from further analysis.
Before skin closure, a 3-ml 2% lidocaine solution was administered into the epidural space to confirm adequate placement of the epidural catheter, and a CADD™ Administration set, Model 6,300 (Smiths Medical, St Paul, MN, United States), was then connected to each patient. Patients were randomized to the receipt of a continuous epidural infusion with PCEA of one of the four solutions using the sealed-envelope technique: a R1 group, 0.1% ropivacaine (AstraZeneca AB, Sodertalje, Sweden); a R2 group, 0.15% ropivacaine; a R1S group, 0.1% ropivacaine +0.5 μg/ml of sufentanil (Yichang Humanwell pharmaceutical, Hubei, China); and a R2S group, 0.15% ropivacaine +0.5 μg/ml of sufentanil. Dosage was a 4-ml/hour background infusion with a bolus dosage of 4 ml/20 min as needed, and a maximal dosage of 16 ml/h.
A blinded observer evaluated the patients. The primary outcome was pain scores as measured using a numerical rating scale (NRS) (0–10 cm: 0, no pain; 10, worst pain imaginable): NRS pain scores at rest (NRS-R), NRS pain scores during movement (NRS-M), and NRS pain scores when massaging the uterus (NRS-U) (Nie et al., 2017) at 6 and 24 h after skin closure. Overall patient satisfaction scores (0–10: 0, dissatisfied; 10, very satisfied) (Tonosu et al., 2020) were recorded 24 h. Sedation was assessed using the Ramsay Sedation Scale: 1, anxious and restless or agitated or both; 2, cooperative, tranquil, and oriented; 3, somnolent, responds to commands only; 4, asleep, shows brisk response to loud auditory stimulus or light glabellar tap; 5, asleep, shows sluggish response to loud auditory stimulus or light glabellar tap; and 6, asleep, shows no response to loud auditory stimulus or light glabellar tap (Nie et al., 2017). The time of first ambulation (able to walk with help) and the time of first flatus were recorded. If the patient persisted with pain, flurbiprofen axetil (Beijing Tide pharmaceutical, Beijing, China) was intravenously injected and documented. We surveilled for ADRs including pruritus, nausea and vomiting, numbness, headache, and dizziness. We also recorded any hypotension (20% below baseline blood pressure, baseline blood pressure was defined as the blood pressure in the preoperative assessment or the usual blood pressure at home) (Siddik-Sayyid et al., 2014; Nie et al., 2017) or respiratory depression (respiratory rate <8 breaths/min).
In this study, analgesic efficacy was the primary outcome. A power analysis showed that 42 patients in each group would provide 80% of the power needed to detect differences among the four groups.
We performed all statistical analyses with SPSS 25.0 software, and statistical significance was set at p = 0.05 (2-sided). A Shapiro-Wilk test, Q-Q plot, and p-p plot were used to confirm normality for continuous variables. All normally distributed continuous variables are reported as means ± SD, and non-normally distributed continuous variables are described as medians (25–75% interquartile range [IQR]). One-way ANOVA or Kruskal-Wallis methods were used to compare the differences between/among groups, and Tukey’s and Dscf tests were used to perform the post-hoc analyses. The Chi-squared test was used to compare the differences between categorical variables, and data are expressed as N (%) patients.
Of the 303 patients screened for eligibility, we enrolled 240 patients, and 42 patients were excluded prior to randomization (Figure 1). One hundred and ninety-eight patients were subsequently randomly allocated to four groups. After randomization, 24 patients were excluded (Figure 1). We ultimately analyzed 43 patients in the R1 group, 45 in the R2 group, 43 in the R1S group, and 43 in the R2S group (Figure 1).
FIGURE 1. Study flow-chart. R1 group, 0.1% ropivacaine; R2 group, 0.15% ropivacaine; R1S group, 0.1% ropivacaine +0.5 μg/ml of sufentanil; R2S group, 0.15% ropivacaine +0.5 μg/ml of sufentanil. CS, cesarean section.
Patient Demographics and Surgical Characteristics
Baseline characteristics for the four groups are shown in Table 1. There were no statistically significant differences among the four groups with respect to age, height, weight, gestational age at delivery, parity, the duration of surgery, infusion volume, estimated blood loss, the puncture interspace location, or the dose of intrathecal 0.5% hypobaric bupivacaine (all p > 0.05).
Postoperative NRS Scores
Six hours after skin closure, NRS-R scores in the R1S (3 [2–3]) and R2S (2 [1–3]) groups were lower than those in either the R1 (3 [3–4]) (p < 0.05, p < 0.001, respectively) or R2 groups (3 [2–4]) (p < 0.05, p < 0.01, respectively). At 24 h after skin closure, there were no statistically significant differences in NRS-R scores among the four groups (p > 0.05) (Figure 2A).
FIGURE 2. (A) Numerical rating scale of pain scores at rest (NRS-R) at 6 and 24 h after skin closure. (B) Numerical rating scale of pain scores during movement (NRS-M) at 6 and 24 h after skin closure. (C) Numerical rating scale of pain scores when massaging the uterus (NRS-U) at 6 h and 24 h after skin closure. R1 group, 0.1% ropivacaine; R2 group, 0.15% ropivacaine; R1S group, 0.1% ropivacaine +0.5 μg/ml of sufentanil; R2S group, 0.15% ropivacaine +0.5 μg/ml of sufentanil. Data are expressed as medians (25–75% IQR). *p < 0.05, #p < 0.01, &p < 0.001.
We noted that at 6 h after skin closure, NRS-M scores in the R1S group (4 [3–5]) were lower than those in the R2 group (5 [4–6]) (p < 0.05), and NRS-M scores in the R2S group (4 [3–5]) were lower than in the R1 (5 [4–6]) (p < 0.05) and R2 (5 [4–6]) (p < 0.01) groups. By 24 h after CS, there were no longer any statistically significant differences in NRS-M scores among the four groups (p > 0.05) (Figure 2B).
By 6 h after skin closure, NRS-U scores in the R2S group (6 [5–6]) were lower than those in the R1 group (7 [6–8]) (p < 0.01), but there was no statistically significant differences between R1S and R1 groups (p > 0.05). By 24 h after CS, there were no statistically significant differences in scores among the four groups (p > 0.05) (Figure 2C).
Patient satisfaction scores were significantly higher in the R2S group (9 [8–10]) relative to the R1 group (8 [6–8]) (p < 0.01). There were no statistically significant differences between any of other two groups (all p > 0.05) (Figure 3).
FIGURE 3. Patient’s overall satisfaction measured 24 h after cesarean section. R1 group, 0.1% ropivacaine; R2 group, 0.15% ropivacaine; R1S group, 0.1% ropivacaine +0.5 μg/ml of sufentanil; R2S group, 0.15% ropivacaine +0.5 μg/ml of sufentanil. Data are expressed as medians (25–75% IQR). #p < 0.01.
The time to patient’s first flatus was shorter in the R2S group (18.7 ± 11.8 h) compared to the R1 group (25.9 ± 12.0 h) (p < 0.05) (Figure 4).
FIGURE 4. Time to patient’s first flatus after cesarean section. R1 group, 0.1% ropivacaine; R2 group, 0.15% ropivacaine; R1S group, 0.1% ropivacaine +0.5 μg/ml of sufentanil; R2S group, 0.15% ropivacaine +0.5 μg/ml of sufentanil. Data are expressed as means ± SD. *p < 0.05.
Requirements for Concomitant Analgesics
The number of self-administered doses of the patient-controlled analgesia (PCA) in the R2S group (0 [0–2]) was less than in the R1 (1 [0–3]) (p < 0.05) and R2 groups (1 [0–4]) (p < 0.05), and that was less in the R1S group (0 [0–2]) than in the R2 group (1 [0–4]) (p < 0.05) at 6 h, while there were no statistically significant differences among the groups at 24 h (p > 0.05). There were no statistically significant differences among the groups regarding the time when highest pain scores were recorded (p > 0.05) or the number of patients who requested supplementary analgesia, either at 6 or 24 h (all p > 0.05) (Table 2).
Recovery of Motor Function
The time to patient’s first ambulation was shorter in the R2S group (24.8 [22.5–27.5 h]) than in the R1S group (27.3 [25.0–28.5 h]) (p < 0.05). There were no statistically significant differences between any of other two groups (all p > 0.05) (Table 2).
We observed no statistically significant differences in Ramsay Sedation Scale scores among the four groups (p > 0.05) (Table 2).
Adverse Drug Reactions
Patients in the R1S group (4 [9.3%]) had a higher incidence of pruritus at 6 h compared to the R1 (0 ) (p < 0.05) and R2 groups (0 ) (p < 0.05), while patients in the R2S group (4 [9.3%]) exhibited a higher incidence of pruritus at 6 h compared to the R2 group (0 ) (p < 0.05). The incidence of numbness in the R2 (22 [48.9%], p < 0.05; 22 [48.9%], p < 0.05) and R2S groups (23 [53.5%], p < 0.01; 23 [53.5%], p < 0.01) was greater than in the R1 group (10 [23.3%], 10 [23.3%]) at both 6 and 24 h. There were no statistically significant differences among the groups regarding other ADRs, including nausea and vomiting, headache, dizziness, hypotension, or respiratory depression (all p > 0.05) (Table 3).
Postoperative analgesia after CS is challenging since we need not only to consider maternal comfort, but the anesthetic technique should also have no ADRs on the newborn. Epidural morphine is commonly used for analgesia after CS (Carvalho and Butwick, 2017), but there is a concomitantly higher incidence of pruritus, nausea and vomiting (Youssef et al., 2014). As these ADRs diminish overall patient satisfaction, we advocate the use of low concentrations of local anesthetics with other opioids so as to reduce opioid dosage and thereby decrease the incidence of ADRs.
The present study indicated that co-administration 0.15% ropivacaine with 0.5 μg/ml of sufentanil epidurally alleviated CS pain at rest, during movement, and when massaging the uterus, and it reduced the number of self-administered doses of the PCA compared to 0.1% ropivacaine or 0.15% ropivacaine at 6 h. Moreover, it improved overall patient satisfaction scores and reduced the time to first flatus compared to 0.1% ropivacaine. The time to first ambulation was not delayed. However, co-administered with sufentanil increased the incidence of pruritus compared to ropivacaine only at 6 h. Higher concentration of ropivacaine increased the incidence of numbness compared to lower concentration at both 6 and 24 h, whether or not it was co-administered with sufentanil. We believe that although a higher incidence of pruritus and numbness was demonstrated, co-administration of 0.15% ropivacaine with 0.5 μg/ml of sufentanil epidurally may be the better choice for pain relief relative to the other groups due to the lower NRS-R, NRS-M, and NRS-U scores, shorter time to first flatus, and higher patient-satisfaction scores.
Published guidelines advocate for fentanyl and sufentanil for epidural analgesia (Plante and Gaiser, 2017). The authors of a systematic review found that compared with fentanyl, sufentanil was more effective in extending the duration of analgesia when used in CSEA during labor (Zhi et al., 2020). Ropivacaine blocks conduction in the sensory and motor nerves, while sufentanil interrupts pain transmission in the dorsal horn. Therefore, adding sufentanil to ropivacaine may synergistically prolong the duration of sensory block (Parpaglioni et al., 2009). In the present study, ropivacaine co-administered with sufentanil relieved the pain not only at rest but also during movement compared to ropivacaine only at 6 h. However, when massage the uterus, 0.15% ropivacaine with sufentanil showed an improved analgesic effect, while 0.1% ropivacaine with sufentanil did not show improvement compared with 0.1% ropivacaine only at 6 h. All these results indicated that a higher concentration of ropivacaine (0.15%) with sufentanil produced a stronger analgesic effect.
Although NRS scores were significantly lower in the R2S group relative to the other groups, the analgesic effect was not satisfactory in any group when massage the uterus. Carvalho et al. found that patients tolerated moderate pain rather than exposing their baby to any possible harmful effects of analgesics (Carvalho et al., 2005), and others found that pain was not the only factor that determined overall patient satisfaction (Schyns-Van Den Berg et al., 2015); these may be reasons for the high overall satisfaction scores we received. In our study, the rare use of supplementary analgesia may be also attributed—at least partially—to the patients’ fear of exposing their baby to any possible harmful analgesics (Carvalho et al., 2005).
Postoperative pain increases the secretion of catecholamines, and sympathetic stimulation prevents the release of acetylcholine (Cho et al., 2017), thus inhibiting the recovery of gastrointestinal function; this may be the reason that time to first flatus in the R1, R2, and R1S groups was longer than that in the R2S group.
Early movement hastens postpartum recovery (Macones et al., 2019). Epidural analgesia with local anesthetics may delay ambulation of the mother, but when administered at low concentrations, the probability is small (Chen et al., 2014). In our study, the time to first ambulation in the R2S group was shorter than R1S group, this maybe attribute to the better analgesic effect in the R2S group than in the R1S group. The time to first ambulation in the R2S group was not delayed compared with the other groups. We attribute this to better analgesic effect and the administration of low-concentration ropivacaine (0.1% or 0.15%). Other investigators also reported similar results, Liu et al. found that 0.2% ropivacaine induced a 30% incidence in motor block, but not in those individuals who received 0.05% or 0.1% ropivacaine (Liu et al., 1999).
Complications of neuraxial drugs are the results of drug absorption into the blood circulation or presence in cerebrospinal fluid, or both. The principal ADRs observed in the present study were numbness and pruritus. The incidence of numbness was higher in the R2 and R2S groups when compared with the R1 group at both 6 h and 24 h, indicating that higher concentration of ropivacaine (0.15%) increased numbness.
The incidence of pruritus was higher in the R2S group relative to the R2 group, and that was higher in the R1S group compared to the R1 and R2 groups at 6 h. But the incidence of pruritus in the present study was overall low (9.3% and 7.0% at 6 and 24 h, respectively, in the R2S group; and 9.3% and 7.0% at 6 and 24 h, respectively, in the R1S group). By contrast, the incidence of epidural morphine (2.5 mg)-induced pruritus was 44% (Youssef et al., 2014). Our use of a small effective dose of sufentanil and the addition of ropivacaine might explain the low incidence of pruritus. Cai et al. reported that when ropivacaine was combined with sufentanil for labor analgesia, the incidence of pruritus was 3.3% (lower than what we reported herein), which may be due to the lower concentration of sufentanil (0.3 μg/ml) the authors used (Cai et al., 2020). Pruritus may, at times, be more unpleasant for patients than pain, from this perspective, epidural sufentanil appears to be better than morphine.
With respect to other ADRs such as nausea and vomiting, headache, dizziness, hypotension, and respiratory depression, there were no significant differences among the four groups.
There were some limitations to our study. First, we did not assess the possible preoperative confounding factors for pain after CS (Pan et al., 2013). However, the previous pain experience due to a preceding CS was evenly distributed among the four groups. Second, the observation period was the initial 24 h, and we recommend that future studies lengthen the observation time to 48 h or even longer. Third, in the present study, the incidence of urinary retention was not recorded, as the urinary catheter was inserted prior to surgery and removed after patients could walk with assistance in the ward.
Although the ADRs (pruritus and numbness) were greater in the R2S group, by significantly reducing the pain scores and the time to first flatus, patients reported higher satisfaction scores in the R2S group relative to other groups. In conclusion, the epidural co-administration of 0.15% ropivacaine and 0.5 μg/ml of sufentanil (at a 4 ml/h background infusion with a bolus dosage of 4 ml/20 min as needed) may be the better choice for post-cesarean analgesia compared to the other three regimens investigated in this study.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
The studies involving human participants were reviewed and approved by the Ethics Committee of the Xuanwu Hospital of Capital Medical University. The patients/participants provided their written informed consent to participate in this study.
F-FM, YL, and T-LW designed the project; K-PF performed the spinal-epidural anesthesia; R-XH monitored the patients; Q-FD observed the patients; F-FM and X-XF analyzed the data; F-FM and DJ wrote the manuscript; LF and T-LW revised the manuscript. All authors approved the final version of the manuscript.
This study was funded by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201818) and the Beijing Municipal Health Commission (Jing 2019-2).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
We thank LetPub (www.letpub.com) for its linguistic assistance and scientific consultation during the preparation of this manuscript.
Bullingham, A., Liang, S., Edmonds, E., Mathur, S., and Sharma, S. (2018). Continuous epidural infusion vs programmed intermittent epidural bolus for labour analgesia: a prospective, controlled, before-and-after cohort study of labour outcomes. Br. J. Anaesth. 121, 432–437. doi:10.1016/j.bja.2018.03.038
Cai, S., Zheng, J., Meng, Q., Chai, J., Ma, R., Wang, Y., et al. (2020). Investigation of the minimum local analgesic concentration of epidural sufentanil combined with ropivacaine for labor analgesia. Clin. Ther. 42, 210–219. doi:10.1016/j.clinthera.2019.10.011
Carvalho, B., Cohen, S. E., Lipman, S. S., Fuller, A., Mathusamy, A. D., and Macario, A. (2005). Patient preferences for anesthesia outcomes associated with cesarean delivery. Anesth. Analg. 101, 1182–1187. doi:10.1213/01.ane.0000167774.36833.99
Chen, S. Y., Liu, F. L., Cherng, Y. G., Fan, S. Z., Leighton, B. L., Chang, H. C., et al. (2014). Patient-controlled epidural levobupivacaine with or without fentanyl for post-cesarean section pain relief. Biomed. Res. Int. 2014, 965152. doi:10.1155/2014/965152
Cho, J. S., Kim, H. I., Lee, K. Y., Son, T., Bai, S. J., Choi, H., et al. (2017). Comparison of the effects of patient-controlled epidural and intravenous analgesia on postoperative bowel function after laparoscopic gastrectomy: a prospective randomized study. Surg. Endosc. 31, 4688–4696. doi:10.1007/s00464-017-5537-6
Gogarten, W., Van De Velde, M., Soetens, F., Van Aken, H., Brodner, G., Gramke, H. F., et al. (2004). A multicentre trial comparing different concentrations of ropivacaine plus sufentanil with bupivacaine plus sufentanil for patient-controlled epidural analgesia in labour. Eur. J. Anaesthesiol. 21, 38–45. doi:10.1017/s0265021504001073
Hirose, M., Hara, Y., Hosokawa, T., and Tanaka, Y. (1996). The effect of postoperative analgesia with continuous epidural bupivacaine after cesarean section on the amount of breast feeding and infant weight gain. Anesth. Analg. 82, 1166–1169. doi:10.1097/00000539-199606000-00011
Jin, J., Peng, L., Chen, Q., Zhang, D., Ren, L., Qin, P., et al. (2016). Prevalence and risk factors for chronic pain following cesarean section: a prospective study. BMC Anesthesiol. 16, 99. doi:10.1186/s12871-016-0270-6
Liang, J., Mu, Y., Li, X., Tang, W., Wang, Y., Liu, Z., et al. (2018). Relaxation of the one child policy and trends in caesarean section rates and birth outcomes in China between 2012 and 2016: observational study of nearly seven million health facility births. BMJ 360, k817. doi:10.1136/bmj.k817
Liu, S. S., Moore, J. M., Luo, A. M., Trautman, W. J., and Carpenter, R. L. (1999). Comparison of three solutions of ropivacaine/fentanyl for postoperative patient-controlled epidural analgesia. Anesthesiology 90, 727–733. doi:10.1097/00000542-199903000-00014
Macones, G. A., Caughey, A. B., Wood, S. L., Wrench, I. J., Huang, J., Norman, M., et al. (2019). Guidelines for postoperative care in cesarean delivery: enhanced Recovery after Surgery (ERAS) Society recommendations (part 3). Am J. Obstet. Gynecol. 221, 247–249. doi:10.1016/j.ajog.2019.04.012
Matsota, P., Batistaki, C., Apostolaki, S., and Kostopanagiotou, G. (2011). Patient-controlled epidural analgesia after Caesarean section: levobupivacaine 0.15% versus ropivacaine 0.15% alone or combined with fentanyl 2 µg/ml: a comparative study. Arch. Med. Sci. 7, 685–693. doi:10.5114/aoms.2011.24140
Matsota, P. K., Markantonis, S. L., Fousteri, M. Z., Pandazi, A. K., Manikis, D. E., Christodoulopoulou, T. C., et al. (2009). Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. Reg. Anesth. Pain Med. 34, 126–129. doi:10.1097/AAP.0b013e3181958f39
Nie, J. J., Sun, S., and Huang, S. Q. (2017). Effect of oxycodone patient-controlled intravenous analgesia after cesarean section: a randomized controlled study. J Pain Res. 10, 2649–2655. doi:10.2147/jpr.s142896
Pan, P. H., Tonidandel, A. M., Aschenbrenner, C. A., Houle, T. T., Harris, L. C., and Eisenach, J. C. (2013). Predicting acute pain after cesarean delivery using three simple questions. Anesthesiology 118, 1170–1179. doi:10.1097/ALN.0b013e31828e156f
Parpaglioni, R., Baldassini, B., Barbati, G., and Celleno, D. (2009). Adding sufentanil to levobupivacaine or ropivacaine intrathecal anaesthesia affects the minimum local anaesthetic dose required. Acta Anaesthesiol. Scand. 53, 1214–1220. doi:10.1111/j.1399-6576.2009.02033.x
Patel, R., Carvalho, J. C., Downey, K., Kanczuk, M., Bernstein, P., and Siddiqui, N. (2017). Intraperitoneal instillation of lidocaine improves postoperative analgesia at cesarean delivery: a randomized, double-blind, placebo-controlled trial. Anesth. Analg. 124, 554–559. doi:10.1213/ane.0000000000001799
Schyns-Van Den Berg, A. M., Huisjes, A., and Stolker, R. J. (2015). Postcaesarean section analgesia: are opioids still required? Curr. Opin. Anaesthesiol. 28, 267–274. doi:10.1097/aco.0000000000000195
Shen, D., Hasegawa-Moriyama, M., Ishida, K., Fuseya, S., Tanaka, S., and Kawamata, M. (2020). Acute postoperative pain is correlated with the early onset of postpartum depression after cesarean section: a retrospective cohort study. J. Anesth. 34, 607–612. doi:10.1007/s00540-020-02789-5
Siddik-Sayyid, S. M., Taha, S. K., Kanazi, G. E., and Aouad, M. T. (2014). A randomized controlled trial of variable rate phenylephrine infusion with rescue phenylephrine boluses versus rescue boluses alone on physician interventions during spinal anesthesia for elective cesarean delivery. Anesth. Analg. 118, 611–618. doi:10.1213/01.ane.0000437731.60260.ce
Tonosu, J., Oshima, Y., Takano, Y., Inanami, H., Iwai, H., and Koga, H. (2020). Degree of satisfaction following full-endoscopic cervical foraminotomy. J. Spine Surg. 6, 366–371. doi:10.21037/jss.2020.01.02
Wang, H., Gao, Q., Xu, R., Dong, W., Zhang, Y., and Fan, J. (2019). The efficacy of ropivacaine and bupivacaine in the caesarean section and the effect on the vital signs and the hemodynamics of the lying-in women. Saudi J. Biol. Sci. 26, 1991–1994. doi:10.1016/j.sjbs.2019.07.014
Wu, C. L., Cohen, S. R., Richman, J. M., Rowlingson, A. J., Courpas, G. E., Cheung, K., et al. (2005). Efficacy of postoperative patient-controlled and continuous infusion epidural analgesia versus intravenous patient-controlled analgesia with opioids: a meta-analysis. Anesthesiology 103, 1079–1088. doi:10.1097/00000542-200511000-00023
Youssef, N., Orlov, D., Alie, T., Chong, M., Cheng, J., Thabane, L., et al. (2014). What epidural opioid results in the best analgesia outcomes and fewest side effects after surgery?: a meta-analysis of randomized controlled trials. Anesth Analg 119, 965–977. doi:10.1213/ane.0000000000000377
Zhi, M., Diao, Y., Liu, S., Huang, Z., Su, X., Geng, S., et al. (2020). Sufentanil versus fentanyl for pain relief in labor involving combined spinal-epidural analgesia: a systematic review and meta-analysis of randomized controlled trials. Eur. J. Clin. Pharmacol. 76, 501–506. doi:10.1007/s00228-019-02806-x
Keywords: cesarean section, postoperative pain, analgesia, sufentanil, ropivacaine
Citation: Miao F, Feng K, Feng X, Fan L, Lang Y, Duan Q, Hou R, Jin D and Wang T (2021) The Analgesic Effect of Different Concentrations of Epidural Ropivacaine Alone or Combined With Sufentanil in Patients After Cesarean Section. Front. Pharmacol. 12:631897. doi: 10.3389/fphar.2021.631897
Received: 21 November 2020; Accepted: 14 January 2021;
Published: 22 February 2021.
Edited by:Venkata Kashyap Yellepeddi, The University of Utah, United States
Reviewed by:Niccolò Lombardi, University of Florence, Italy
Caren Lee Hughes, Mayo Clinic Florida, United States
Copyright © 2021 Miao, Feng, Feng, Fan, Lang, Duan, Hou, Jin and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tianlong Wang, email@example.com